A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

Hewitt, D. Brock; Nissen, Nicholas N.; Hatoum, Hassan; Musher, Benjamin; Seng, John E.; Coveler, Andrew L.; Al‐Rajabi, Raed; Yeo, Charles J.; Leiby, Benjamin E.; Banks, Joshua; Balducci, Lodovico; Vaccaro, Gina M.; LoConte, Noelle K.; George, Thomas J.; Brenner, W.; Elquza, Emad; Vahanian, Nicholas N.; Rossi, Gabriela R.; Kennedy, Eugene P.; Link, Charles J.; Lavu, Harish

doi:10.1097/sla.0000000000004669

Cited by 58 publications

(49 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The addition of algenpantucel-L improved both disease-free survival (DFS) and OS (after a median follow-up of 21 months, the 12-month DFS rate was 62%, and the 12-month OS rate was 86%). However, the phase III trial did not confirm the previous findings, showing similar outcomes regardless of the addition of algenpantucel-L to standard treatment [ 123 ].…”

Section: Immunotherapymentioning

confidence: 62%

Hacking Pancreatic Cancer: Present and Future of Personalized Medicine

et al. 2021

View full text Add to dashboard Cite

Pancreatic cancer (PC) is a recalcitrant disease characterized by high incidence and poor prognosis. The extremely complex genomic landscape of PC has a deep influence on cultivating a tumor microenvironment, resulting in the promotion of tumor growth, drug resistance, and immune escape mechanisms. Despite outstanding progress in personalized medicine achieved for many types of cancer, chemotherapy still represents the mainstay of treatment for PC. Olaparib was the first agent to demonstrate a significant benefit in a biomarker-selected population, opening the doors for a personalized approach. Despite the failure of a large number of studies testing targeted agents or immunotherapy to demonstrate benefits over standard chemotherapy regimens, some interesting agents, alone or in combination with other drugs, have achieved promising results. A wide spectrum of therapeutic strategies, including immune-checkpoint inhibitors tyrosine kinase inhibitors and agents targeting metabolic pathways or the tumor microenvironment, is currently under investigation. In this review, we aim to provide a comprehensive overview of the current landscape and future directions of personalized medicine for patients affected by PC.

show abstract

Section: Immunotherapymentioning

confidence: 62%

Hacking Pancreatic Cancer: Present and Future of Personalized Medicine

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Resected patients had an overall survival of 28.7 months compared to 12.6 months in unresected patients. Vaccination did not improve survival in either of the subgroups (6).…”

mentioning

confidence: 77%

“…HepatoBiliary Surg Nutr 2021 | https://dx.doi.org/10.21037/hbsn-21-238 borderline resectable or unresectable, locally advanced pancreatic cancer (6). Algenpantucel-L is an intradermal vaccine made of two irradiated pancreatic cancer cell lines genetically modified to express murine α1,3galactosyltransferase.…”

mentioning

confidence: 99%

“…Following a one-arm phase II study of 70 patients that received adjuvant chemotherapy and radiochemotherapy in combination with algenpantucel-L, the randomized phase III IMPRESS study with 722 patients was conducted, but was negative for the primary endpoint of overall survival (NewLink Genetics May 9, 2016). In the PILLAR study, 303 patients with borderline resectable (n=53) or locally advanced pancreatic cancer (n=250) were treated with chemotherapy followed by chemoradiation and randomized to either receive concomitant immunotherapy with Algenpantucel-L or not (6). The induction chemotherapy protocol was up to the investigator; about two-thirds of the patients received FOLFIRINOX, the others gemcitabine/ nab-paclitaxel.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Perioperative immunotherapy for pancreatic cancer is on its way

Springfeld¹,

Bailey²,

Hackert³

et al. 2021

Hepatobiliary Surg Nutr

View full text Add to dashboard Cite

show abstract

“…The mechanism of action was based on the epitope spreading, which amplified the host immune response, leading to the death of PDAC cells by activation of antibody-dependent cell-mediated cytotoxicity. Unfortunately, the trial did not show any benefit in survival by adding algenpantucel-L to the chemotherapy if compared with the control arm (median overall survival 14.3 vs. 14.9 months, respectively; HR: 1.02, p = 0.98) [93].…”

Section: Immunotherapy In the Neo-adjuvant Setting For Pdacmentioning

confidence: 95%

Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome?

Khakoo

Petrillo

Salati

et al. 2021

Cancers

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) has an aggressive tumor biology and is associated with poor survival outcomes. Most patients present with metastatic or locally advanced disease. In the 10–20% of patients with upfront resectable disease, surgery offers the only chance of cure, with the addition of adjuvant chemotherapy representing an established standard of care for improving outcomes. Despite resection followed by adjuvant chemotherapy, at best, 3-year survival reaches 63.4%. Post-operative complications and poor performance mean that around 50% of the patients do not commence adjuvant chemotherapy, and a significant proportion do not complete the intended treatment course. These factors, along with the advantages of early treatment of micrometastatic disease, the ability to downstage tumors, and the increase in R0 resection rates, have increased interest in neo-adjuvant treatment strategies. Here we review biomarkers for early diagnosis of PDAC and patient selection for a neo-adjuvant approach. We also review the current evidence for different chemotherapy regimens in this setting, as well as the role of chemoradiotherapy and immunotherapy, and we discuss ongoing trials.

show abstract

A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

Cited by 58 publications

References 21 publications

Hacking Pancreatic Cancer: Present and Future of Personalized Medicine

Hacking Pancreatic Cancer: Present and Future of Personalized Medicine

Perioperative immunotherapy for pancreatic cancer is on its way

Neoadjuvant Treatment for Pancreatic Adenocarcinoma: A False Promise or an Opportunity to Improve Outcome?

Contact Info

Product

Resources

About